Takeda Pharmaceutical Co has agreed to sell its Japanese consumer healthcare business to US investment fund Blackstone Group for 242 billion yen ($2.3 billion), Japan’s largest drugmaker said on Monday.
The sale of Takeda Consumer Healthcare Company, which makes over-the-counter (OTC) drugs and health products, is expected to close by March 31, subject to regulatory closing conditions, the company said in a statement.
Takeda has been reducing its OTC assets worldwide as it seeks to refocus its business and reduce debt after its $59-billion acquisition of Shire.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.